STAMFORD, Conn. --(BUSINESS WIRE)--Oct. 3, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024 .
STAMFORD, Conn. --(BUSINESS WIRE)--Sep. 27, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of September 23, 2024 , the compensation committee of GeneDx’s board of directors granted a total of 7,700 restricted
STAMFORD, Conn. --(BUSINESS WIRE)--Aug. 12, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall: UBS Genomic Medicine Summit – August 13-14, 2024
STAMFORD, Conn. --(BUSINESS WIRE)--Aug. 9, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024 , the compensation committee of GeneDx’s board of directors granted seven newly hired employees
Faster Turnaround Time for Rapid Whole Genome Sequencing (rWGS), Buccal Sample Types and Additional Repeat Expansions to Become Commercially Available STAMFORD, Conn. --(BUSINESS WIRE)--Jul. 30, 2024-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights,
Reported second quarter 2024 revenue from continuing operations 1 of $68.9M with 77% year-over-year growth of exome and genome test revenue Expanded second quarter 2024 adjusted gross margins 2 from continuing operations to 62% Narrowed second quarter 2024 adjusted net loss 2 to $2.7M Raising
STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024.
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City,